Xcel Research LLC: FDA Warning Letter 694608-12102024

Updated August 21, 2026

Xcel Research LLC, operator of xcelpeptides.com, received FDA warning letter 694608-12102024 on December 10, 2024. The letter records an agency review of the site conducted in October 2024 and reproduces seven product names as the storefront displayed them, from "RETA" to "SERMORELIN," within the batch's shared unapproved-new-drug determination.

The October 2024 review

According to the letter, FDA staff examined xcelpeptides.com in October 2024. What the letter preserves from that review is, above all, an inventory: the agency copied the storefront's product names into the record verbatim, capitalization and coinages intact. The determination that followed matched the rest of the same-day batch — GLP-1-class products offered under research-use-only labels that FDA judged, on the evidence of the site itself, to be intended for human use as drugs — together with the standard direction to respond in writing within 15 working days. Both the review date and the legal characterization are the agency's, taken from the published letter.

Products named in the letter

The seven names below appear in this record solely because letter 694608-12102024 lists them. This index reproduces the strings as printed and attaches no claim, characterization, or finding of its own to any compound.

What a product-name inventory documents

When a warning letter reproduces a storefront's product names, the resulting list serves several documentary functions worth separating:

A dated snapshot. Storefronts change; the letter fixes what xcelpeptides.com displayed at the moment of the October 2024 review. Whatever the site showed later, the record of that month is preserved on fda.gov.

The scope of the determination. The list defines which listings the agency's unapproved-new-drug conclusion attached to. It is a statement about those named offerings as marketed — not a finding about any compound as a class, and not a laboratory analysis of anything sold.

The naming itself as evidence. The letter captures the names in the exact forms the site used — abbreviations and a coined blend name alongside full compound names. In later enforcement, FDA would weigh naming conventions on peptide storefronts as part of the evidentiary picture; the Xcel inventory shows the kind of raw material such assessments start from.

What an inventory does not do is equally part of the record: it assigns no qualities to the compounds, reports no test results, and states nothing about purchasers. Readers wanting the primary document will find the letter short and public, linked first under Sources.

Batch position

Letter 694608-12102024 is one of four FDA warning letters to research-peptide vendors dated December 10, 2024, alongside those to Prime Vitality Inc dba Prime Peptides, Summit Research Peptides, and SwissChems. FDA's December 17, 2024 Roundup summarized the batch. Its place in the 2024–2026 sequence of peptide-vendor enforcement is charted on the enforcement timeline; entity records across the sector are collected in the vendor index.

Sources

1. FDA Warning Letter 694608-12102024, Xcel Research LLC — the primary record, including the product list.
2. FDA Warning Letter 695156-12102024, Prime Vitality Inc dba Prime Peptides — same-day batch letter.
3. FDA Warning Letter 695607-12102024, Summit Research Peptides — same-day batch letter.
4. FDA Warning Letters index (searchable) — for the SwissChems batch letter.
5. FDA Roundup, December 17, 2024 — agency summary of the batch.

Further reading

1. Full vendor index — every entity record
2. Artemis Labs: catalog breadth versus verification depth, read through letter 694608-12102024

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.